The objective of this study was to test a topical formulation of EPHX2 inhibitor, GSK2256294, in 20 a dermal wound diabetic (db/db) mouse model. Comparisons were made between groups 6/10 reached at least 50% closure by the study conclusion. Nine of ten wounds achieved 30 complete closure in the positive control group by 21 days. Although the EPHX2 inhibitor results 31 were indicative of efficacy, the single-sided p-value criterion of 0.05 was not met in this study. 32 33
2 21 treated with EPHX2 inhibitor, matching vehicle control and a currently approved treatment for 22 diabetic ulcers, becaplermin/Regranex, as a positive control which is highly efficacious in this 23 model. Leptin receptor-deficient (db/db) male mice were sequentially assigned to treatment 24 groups (N=10 per group) based on blood glucose levels and body weight. Mice were given a 25 single 8 mm diameter full thickness wound on the back. Wounds were photographed and 26 traced, and fresh test materials applied periodically with fresh dressing. Of ten mice treated 27 with GSK2256294, three had completely healed wounds at the study conclusion, and 8/10 mice 28 reached at least 50% closure. In the vehicle group, no mice achieved complete closure, and only Although the molecular mechanisms of action of EETs have not been completely elucidated, it 47 is hypothesized that the therapeutic effects of sEH inhibition are mediated by the accumulation 48 of EETs and that many potentially beneficial actions of EETs are attenuated by the conversion of 49 EETs to the less active DHETs. Therefore, sEH inhibition is a potential therapeutic target to 50 enhance the beneficial effects of EETs (1). GSK2256294 is a potent and selective soluble epoxide 51 hydrolase (sEH) inhibitor (2) which has previously been studied in preclinical models (3, 4) and 52 in phase I clinical trials (5, 6).
54
Chronic wounds, including pressure ulcers, leg ulcers and diabetic foot ulcers are an area of 55 significant unmet need. Thousands of lower limb amputations are performed annually on 56 diabetic patients. One estimate of the direct cost of diabetes treatments in the US in 2007 was 57 $116 billion, of which one third was linked to treating foot ulcers (7) . Recognizing that diabetic 58 wound healing is a very challenging paradigm, we hypothesized that inhibition of sEH would 59 result in improved resolution of chronic wounds and could lead to a potentially 60 transformational medicine for patients. We therefore proceeded to test GSK2256294 in a 61 validated diabetic wound healing model to investigate this hypothesis. Harlan, San Diego, CA) and acidified water (pH 2.7-3.0) throughout the study period. The 6 104 bedding material was hardwood chips (Sani-Chips, Cat # 7115, Harlan, CA, USA) and was 105 changed weekly to ensure the ammonia levels within each cage were below 24 ppm. 106 107 Animals were acclimated to the housing environment for 7 days prior to the initiation of the 108 study. During the acclimation period, the general health of the animals was monitored daily. 109 Animals appeared normal and did not exhibit signs of poor health. No animals were excluded 110 from this study. Glucose and body weight were measured on Day -1, and treatment groups 111 were assigned sequentially to animals ordered by their Day -1 glucose levels (e.g., 1, 2, 3, 4, 5, The log-rank test was used to compare treatment groups by their survival. 194 Baseline-normalized wound area under the curve (AUC) was also computed for each mouse, 195 and group means and standard errors were reported, using a one-way ANOVA. Similarly, 196 wound area AUC was calculated without normalization and was modeled by an ANCOVA model, 197 with baseline wound area as the covariate. Discussion 259 We were encouraged that the GSK2256294-treated group showed evidence of improved 260 healing compared to vehicle control, despite the statistical significance threshold of P < 0.05 not 261 being met. In part, this might be attributed to greater variability in the wound healing process 262 among the mice in this study, compared to baseline data previously seen in this model. 263 Repeating the study with larger group size would be illuminating. We also note that this study 14 264 was our first attempt at topical formulation of GSK2256294. It may be possible to further 265 optimize the formulation, and the dose administered, to obtain improved response. 266 After our study was complete, a publication on EETs and diabetic wound healing appeared (17), 267 demonstrating that 11,12-EET treatment accelerated wound healing in ob/ob (leptin-deficient) 268 mice. These mice also had significantly reduced mRNA and protein expression of CYP2C65 and 269 CYP2J2 compared to wild type. Taken together, the data strongly suggests that sEH inhibition, 270 or other strategies to raise EET levels, can potentially improve wound healing in pre-clinical 271 diabetic models. 
